Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07496190Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2026
- Primary completion
- Feb 2032
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-free survival at 3 years. Started Feb 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07496190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07496190.